Introduction
============

Heat shock proteins (HSPs) are a group of molecular chaperones that help proteins fold into their native conformation, and protect cells from stressful environments. However, certain HSPs are overexpressed by malignant cells to survive various therapies, inhibit cancer cells from undergoing senescence and apoptosis, stabilize the lysosome membrane and promote autophagy [@B1]. Among the HSP family, HSP27, HSP60, HSP70 and HSP90 are the most well-known and most widely studied. Importantly, HSP90 inhibition sensitizes tumor cells to chemotherapy-induced death [@B2]. Treatment with the HSP90 inhibitor (17-DMAG) promotes breast cancer stem cell necrosis in nanoparticle-based photothermal therapies [@B3]. Therefore, the quantitative detection and downregulation of the HSP90 expression level are of great value for cancer diagnosis and therapy. Currently, quantitative real-time polymerase chain reaction (*q*RT-PCR) and microarray analysis are the standard methods for mRNA detection [@B4], which can reveal the average mRNA levels in cell lysates from a large number of cell groups rather than individual living cells [@B5]. Recently, hairpin-structured molecular beacons (MBs) have found numerous applications in carcinogenesis studies and medical therapy due to their nucleic acid recognition and sensitive Förster resonance energy transfer (FRET) property [@B6]. For example, Tan and co-workers designed label-free MBs for the selective detection of DNA, RNA, and protein in TMB buffer [@B7]. MBs have also used to detect exosomal miR-21 *in situ* [@B8].

Antisense oligonucleotides were wieldy used to promote RNA cleavage and degradation by nuclease activation to regulate tumor-related gene expression [@B9] or to inhibit translation by occupancy-only mechanisms [@B10]. However, RNA and DNA oligonucleotides, including MBs, are rapidly degraded under physiological conditions, and the negatively charged oligonucleotides are difficult to internalize into cancer cells; therefore, they have limited utility as therapeutic agents [@B11]. Fortunately, the advent of nanotechnology has led to the development of different kinds of gene delivery systems, such as mesoporous silica nanoparticles [@B12], nanographene [@B13], PLGA-based nanoparticles [@B14], gold nanoparticles [@B15], and iron oxide nanoparticles. Such delivery systems are able to protect and transfer plasmid DNA [@B16], [@B17], oligonucleotides [@B18] and fluorescent probes [@B19] into living cells. For example, Choi et al. constructed nanoprobes from iron oxide nanoparticles (IONPs) and hairpin MBs to detect miR-200a in living cells [@B20]; Yin et al. utilized PEI coated magnetic core-shell nanoparticles to deliver a heat-inducible gene vector that encodes TRAIL into mesenchymal stem cells [@B21]. It has been reported that a CD44-targeting HSP72 depletion nanosystem was fabricated to selectively sensitize MDA-MB-231 cells to hyperthermia and enhance therapeutic efficacy with minimal side effects both *in vitro* and *in vivo* [@B22]. Moreover, since IONPs are able to shorten the T2 relaxation time of water protons, they enhanced imaging contrast and sensitivity in MR imaging; therefore, various sizes and shapes for IONPs have been investigated as *T*~2~-weighted MR imaging contrast agents [@B23]-[@B27]. Together with drug/gene delivery [@B28]-[@B30] and magnetic hyperthermia capacities, IONP-based nanosystems exhibit great potential for advancements in cancer diagnostics and therapies [@B31].

In this work, we designed and synthesized a new kind of nanobeacon, built with cubic-shaped iron oxide nanoparticle (IONC), generation 4 poly(amidoamine) dendrimer (G4 PAMAM), triblock copolymer Pluronic P123 (P123) and HSP90α mRNA-specific molecular beacon (HSP90-MB), to implement HSP90α mRNA quantitative detection and efficient downregulation in living cells and to enhance *T*~2~-weighted MR imaging in a tumor model (Figure [1](#F1){ref-type="fig"}). Thus, it might be a promising application for tumor-related mRNA detection, gene expression regulation and multiscale imaging in the field of theranostic cancer.

Materials and Methods
=====================

Materials
---------

Iron(III) chloride hexahydrate (FeCl~3~·6H~2~O) was purchased from Chron Chemicals (Chengdu, China); oleic acid, sodium oleate (82% and 97%), 1-octadecene (\>90%), meso-2,3-dimercaptosuccinic acid (DMSA), N-(3-dimethylaminopropyl)-N\'-ethylcarbodiimide hydrochloride (EDC), N,N\'-Carbonyldiimidazole (CDI), and N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) were purchased from Aladdin (Shanghai, China); generation 4 poly(amidoamine) dendrimer (G4 PAMAM-NH~2~, 10% in methanol) was purchased from CY Dendrimer Technology (Weihai, China); Pluronic P123 (MW 5800) was purchased from Sigma-Aldrich (St. Louis, MO, USA); TRIzol reagent was purchased from Thermo Fisher Scientific (Waltham, MA, USA); PrimeScript RT Reagent Kit and SYBR Premix Ex Taq II (Tli RNaseH Plus) were purchased from Takara (Dalian, China); CellTiter 96 AQueous One Solution Cell Proliferation Assay was purchased from Promega (Fitchburg, WI, USA); LysoBlue was purchased from KeyGen BioTECH (Jiangsu, China); and 4S GelRed (10000X in water) and human GAPDH endogenous reference gene primers were purchased from BBI (Shanghai, China). All other oligonucleotides were synthesized and purified by Shanghai Sangon Biological Engineering Technology Co., Ltd. (Shanghai, China). All chemicals, if not mentioned, were of analytical grade and used as received without further purification. All aqueous solutions and dispersions were prepared using ultrapure water (≥18 MΩ, Milli-Q, Millipore, Bedford, MA, USA).

The MDA-MB-231 human breast cancer cell line was obtained from the American Type Culture Collection (ATCC), and cell culture products were purchased from GIBCO (Thermo Fisher Scientific, Waltham, MA, USA). The MCF-10A human breast non-tumorigenic cell line and its culture medium were purchased from Procell Life Science&Technology Co., Ltd. (Wuhan, China). An SPF severe immune-deficient strain (NCG) of female mice was purchased from GemPharmatech Co., Ltd (Jiangsu, China).

Instruments
-----------

The 30,000 MWCO Amicon Ultra-4 Centrifugal Filter (Millipore, Bedford, MA, USA) was used to purify and concentrate nanoparticles during synthesis. The JEM-2010 transmission electron microscope (TEM) (JEOL, Tokyo, Japan) was used to characterize the sizes and shapes of nanoparticles. The size distribution, polydispersity index (PDI) and Zeta potential of nanoparticles were measured by dynamic light scattering (DLS) using a Zetasizer (NanoZS, Malvern Panalytical Instruments, UK). Crystalline structures were measured by X-ray diffraction (XRD) (X\'Pert Pro, Malvern Panalytical Instruments, UK). Elemental iron analysis was performed on an ICP-ASE (ICP-OES 730, Agilent Technologies, Santa Clara, CA, USA). The magnetic properties of nanoparticles were measured using an MPMS3 Superconducting Quantum Interference Device (SQUID) magnetometer (Quantum Design, San Diego, CA, USA). Thermogravimetric analysis (TGA) was performed on a thermal analyzer (STA 449 F3, NETZSCH, Selb, Germany). IR spectra were recorded on an FT-IR spectrometer (Nicolet iS5, Thermo Fisher Scientific, Waltham, MA, USA). The *T~1~* and *T*~2~ relaxation time measurement and *T*~2~-weighted MR imaging were performed on a 3T MRI scanner (MR750; GE Discovery, Milwaukee, WI, USA) in the MRI research center, University of Electronic Science and Technology of China. A Fluorescence Microplate Reader (Varioskan Lux, Thermo Fisher Scientific, Waltham, MA, USA) was used to detect the fluorescence properties of nanobeacons. The proliferation assay and hemolysis assay results were recorded by a microplate reader (ELx808; BioTek Instruments, Winooski, VT, USA). Gel images were captured using a UV transilluminator (Bio-Rad, Philadelphia, PA, USA). *q*RT-PCR analysis was performed on a CFX96 Real-Time PCR Detection System (Bio-Rad, Philadelphia, PA, USA). Confocal microscopy was performed on a laser-scanning confocal microscopy system (LSM-800, Carl Zeiss, Oberkochen, Germany). Flow cytometry assays were performed on a Guava easyCyte flow cytometer (Millipore, Bedford, MA, USA).

Synthesis and characterization of nanoparticles
-----------------------------------------------

Detailed synthesis routes of nanoparticles are shown in the [Supporting Information](#SM0){ref-type="supplementary-material"}. For characterization, the sizes and shapes of the IONC-OA, IONC-DMSA, IONC-PAMAM and IPP nanoparticles were determined by TEM. The size distributions of the IONC-OA nanoparticles were analyzed by measuring the edge length of the nanocubes. The crystalline structures of the IONC core were confirmed using the XRD pattern. The concentration of Fe in IONC-DMSA, IONC-PAMAM and IPP nanoparticles was determined by 10% nitric acid digestion at 70 °C and ICP-AES measurement with proper dilution. The hydrodynamic size distribution, PDI and Zeta potential of nanoparticles were measured by DLS in Milli-Q water (pH 7.0). Surface modification of the nanoparticles was characterized by FT-IR. To estimate the modification molecules on the particle surface and their dissociation behavior, TGA was performed from 30 °C to 600 °C at a heating rate of 10 °C min^-1^ under a flow of nitrogen (50 mL min^-1^). The magnetic properties of nanoparticles were measured using an MPMS3 SQUID magnetometer. Field-dependent magnetization curves were measured at 300 K as a function of the external field, ranging from -7 T to 7 T, and hysteresis curves were recorded. Temperature-dependent magnetization in a magnetic field of 60 O~e~ was recorded in the 5 K-300 K temperature range for zero-field-cooled (ZFC) and field-cooled (FC) samples.

Synthesis and characterization of the HSP90AA molecular beacon
--------------------------------------------------------------

The sequence of the HSP90AA (Gene ID: 3320) molecular beacon (HSP90-MB), the primers of HSP90AA and the sequences of targeted or mismatched oligonucleotides were designed using Beacon Designer 8 software and verified by NCBI primer-BLAST. The potential secondary structures and the target recognition ability of HSP90-MB were predicted using NUPAK [@B36]. The sequences of oligonucleotides are shown in Table [S1](#SM0){ref-type="supplementary-material"} in the [Supporting Information](#SM0){ref-type="supplementary-material"}. The target concentrations for the dependent fluorescence recovery property of HSP90-MB was examined using MB-target hybridization experiment. HSP90-MB (64 nM) was incubated with increasing concentrations of the oligonucleotide targets (0-128 nM) in 0.01 M phosphate buffered saline (PBS) at 37 °C for 4 h, and the fluorescence spectrum (Ex = 495 nm) was recorded using a fluorescence microplate reader. The specificity of HSP90-MB was examined by incubating HSP90-MB (64 nM) with target, mismatched, or non-target sequences (0-128 nM) in 0.01 M PBS at 37 °C for 4 h and recording the fluorescence intensity (Ex = 495 nm, Em = 519 nm) by a fluorescence microplate reader.

Preparation and characterization of the IPP/MB nanobeacon
---------------------------------------------------------

To determine the optimal mass ratio of iron in IPP/HSP90-MB nanobeacon, increasing concentrations of IPP (0, 10, 20, 40, 80, 160, 320 μg Fe mL^-1^) were added to the HSP90-MB solution (10 μg mL^-1^) at equal volume. The mixture was vortexed briefly and incubated at 37 °C for 20 min to ensure complex formation. Agarose gel electrophoresis was performed to reveal the condensation ability of different mass ratios of iron in IPP to HSP90-MB [@B32].

To examine the oligonucleotides protection ability of IPP nanoparticles, an agarose gel electrophoresis assay of HSP90-MB protection was performed according to our previous study [@B16]. Briefly, IPP/MB at the mass ratio of 16:1 (IPP (Ferrum) to HSP90-MB) was prepared as described above. 100 μL of samples (0.5 μg HSP90-MB) were incubated with 2 μL DNase I (1 U/μL) at 37 °C for 1 h. Samples were treated with 1 μL of heparin (8 U/μL) at 37 °C for 1 h to release the HSP90-MB. Samples were treated with 10 μL of 25mM EDTA (10X EDTA) and incubated at 65 °C for 10 min to inactivate DNase I. Agarose gel electrophoresis was performed to detect the degradation of HSP90-MB.

The particle size distribution, PDI and Zeta potential of the nanobeacon were measured by DLS after the samples were appropriately diluted in Milli-Q water (pH 7.0).

MR relaxivity assay
-------------------

To evaluate the longitudinal relaxivity (r~1~) and transverse relaxivity (r~2~) of the nanobeacon, 1 mL of aqueous dispersion containing increasing concentrations of nanobeacon (0.02-0.6 mM Fe) was pipetted into 2-mL PE tubes. *T*~1~ and *T*~2~ relaxation time measurement was performed by a clinical 3T MR imaging device in which the tubes were vertically placed inside an animal coil.

*T*~1~ relaxation time was measured using SE-IR sequence with increasing inversion times (TI = 50, 400, 1100 and 2500 ms) according to a previous study [@B33], and *T*~2~ mapping sequence was used to generate MR images with increasing echo times (TE = 10.072 to 80.576 ms) and a fixed repetition time (TR = 2000 ms). The *T*~2~ relaxation time was determined by the following formula [@B34]:

TE~1~ and TE~2~ are different echo times in a *T*~2~ mapping scan, SI~1~ and SI~2~ are the corresponding MR imaging signal intensities in the same region of the corresponding TE image.

The r~1~ and r~2~ relaxivity of each sample were determined by the linear fitting of 1/*T*~1~ and 1/*T*~2~ as a function of the Fe concentration.

Cell culture
------------

The TNBC cell line, MDA-MB-231, was cultured in Leibovitz\'s L-15 medium supplemented with 10% new-born calf serum and 1% penicillin-streptomycin at 37 °C in a humidified incubator. The non-tumorigenic epithelial cell line, MCF-10A, was cultured in a medium that contained 92.6% Dulbecco\'s modified Eagle medium (nutrient mixture F-12 (DMEM/F12), 5% horse serum, 1% penicillin-streptomycin, and 1.4% growth factors) at 37 °C in a 5% CO~2~ humidified incubator.

Cellular uptake of the IPP/MB nanobeacon
----------------------------------------

The IPP/MB nanobeacon (\>600 μg Fe mL^-1^, dispersed in Milli-Q water) was mixed with culture medium to a final concentration of 10 μg Fe mL^-1^. The concentration of HSP90-MB on the nanobeacon was 0.625 μg mL^-1^ (\~54 nM), at a mass ratio of 16:1 (Fe to HSP90-MB). Cells that were seeded at a density of 80% in a 6-well plate and allowed to spread overnight were then incubated with the nanobeacon for another 24 h at 37 °C. The medium was then removed, and the cells were washed with PBS three times, detached by trypsin, centrifuged at 100 *g* for 5 min. The pellet was resuspended in 10% nitric acid, digested at 70 °C, and incubated for 24 h in a constant temperature shaker at 300 rpm. After centrifugation at 2000 *g* for 5 min, the supernatant from the digested cells was obtained to measure the concentration of Fe by ICP-AES with proper dilution.

Cytotoxicity assay
------------------

Cells were seeded in 96-well plates at a density of 80%, allowed to spread overnight, and then incubated with increasing concentrations of IONC-DMSA, PAMAM, IPP nanoparticles or the IPP/MB nanobeacon for another 48 h at 37 °C. A cell proliferation assay was performed using a CellTiter 96 AQueous. The absorbance at 490 nm was recorded by a microplate reader.

Hemolysis assay
---------------

Red blood cells (RBCs) were isolated from fresh rabbit blood by centrifugation at 400 *g* for 10 min. The cells were purified by rinsing five times with PBS. The suspension of RBCs was diluted ten times with PBS and 0.1 mL was added to 0.9 mL of water (positive control), saline (negative control), and saline containing various concentrations of IONC-DMSA, PAMAM, IPP or the IPP/MB nanobeacon. After a gentle shaking, the mixtures were kept still for 2 h at 37 °C. After centrifugation of the mixture (9000 *g*, 1 min), the supernatant (hemoglobin) was transferred to 96-well plates, and the absorbance at 540 nm was recorded by a microplate reader. The percentage hemolysis was calculated using the following equation:

Quantitative real-time RT-PCR for HSP90α mRNA
---------------------------------------------

Approximately 1.0×10^6^ cells were collected for total RNA isolation using TRIzol reagent. Then, 2 μg of total RNA was reverse transcribed to cDNA using the PrimeScript™ RT Reagent Kit. Afterward, 2 μL of cDNA was analyzed by *q*RT-PCR targeting HSP90AA and GAPDH using SYBR Premix Ex Taq II (Tli RNaseH Plus). The analysis was performed on a CFX96 Real-Time System, with relative HSP90α mRNA expression levels determined by the ^ΔΔ^*C~t~* method using Bio-Rad CFX Manager software. The primers used in the *q*RT-PCR assay are shown in Table [S1](#SM0){ref-type="supplementary-material"} in the [Supporting Information](#SM0){ref-type="supplementary-material"}.

Western blot analysis for HSP90α
--------------------------------

Western blot analysis was performed as previously described [@B35]. Briefly, cells lysed in RIPA lysis buffer (Beyotime, China), after being washed in cold PBS, were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, USA). The membranes were blocked with 5% non-fat dry milk in TBST buffer (10 mM Tris-HCl, 100 mM NaCl, and 0.1% Tween-20) for 1 h at room temperature before incubation with HSP90α (Abcam, mouse mAb; 1:1000) and β-actin (Abcam, mouse mAb; 1:1000) primary antibodies. After being washed to remove non-bound primary antibodies, the membranes were incubated with the corresponding secondary antibody at a 1:2000-10000 dilution at room temperature for 2 h. The membranes were washed three times with TBST, and immunoreactive signals were detected using western blot Luminol Reagent (Beyotime, China), according to the manufacturer\'s instructions.

Confocal microscopy assay
-------------------------

MDA-MB-231 or MCF-10A cells were seeded in glass-bottom culture dishes and allowed to spread overnight. For subcellular localization assays, cells were incubated with the IPP/MB nanobeacon (10 μg Fe mL^-1^) for 4 h/24 h/48 h, then washed with PBS several times to remove excess nanobeacon. LysoBlue was used to detect acidic organelles such as lysosomes. For immunofluorescence staining, cells were incubated with the nanobeacon (10 μg Fe mL^-1^) for 24 h. They were then washed with PBS several times to remove the excess nanobeacon and fixed by 4% paraformaldehyde for 15 min at room temperature. Then, cells were permeabilized in 0.1% Triton X-100 for 10 min and blocked in 5% BSA for 1 h at 37 °C. The cells were incubated with HSP90α antibody (Abcam, mouse mAb; 1:100) at 4 °C overnight. Then, cells were incubated with secondary antibody coupled to Alexa Flour 647 for 1 h at 37 °C and washed with PBS before the cell nuclei were stained with DAPI. Finally, the confocal fluorescence images of the cells were obtained on a laser-scanning confocal microscopy system.

Flow cytometry assay
--------------------

MDA-MB-231 or MCF-10A cells were seeded at a density of 80% in a 6-well plate and allowed to spread overnight. Then, cells were incubated with the nanobeacon (10 μg Fe mL^-1^) for 24 h. The medium was removed, and the cells were washed with PBS several times to remove excess nanobeacon and detached by trypsin. The excess trypsin was removed by careful pipetting, and the cell monolayer was gently washed with PBS to collect the detached cells. Flow cytometry was performed on a Guava easyCyte flow cytometer using the green fluorescent channel (488 nm excitation) to evaluate the fluorescent recovery of the IPP/MB nanobeacon.

*In vivo* T~2~-weighted MR imaging of a tumor model
---------------------------------------------------

All animal experiments were performed in agreement with the guidelines of the Institutional Animal Care Committee of the University of Electronic Science and Technology of China (UESTC). The MDA-MB-231 tumor model was established in female 4- to 6-week-old NCG mice by subcutaneously injecting 1.0×10^7^ MDA-MB-231 cells in 100 μL of saline-matrigel mixture (v:v = 1:1) into the right flank region. When tumors reached approximately 4-6 mm in diameter, the mice were randomly divided into two groups: saline or IPP/MB. A total of 100 μL of saline or IPP/MB (30 μg Fe mL^-1^, in 100 μL saline) was intravenously injected via the tail vein. *T*~2~-weighted MR images were obtained before injection and at time points 2, 4, 6, and 24 h postinjection by a clinical 3T MR imaging system with an animal coil. The mice were anesthetized with 2.5% isoflurane in air at a flow rate of 0.3 L min^-1^ and placed inside the animal coil. 3D FSE Cube *T*~2~-weighted MR images were obtained with a 2-mm slice thickness, 2000/59.568 ms TR/TE, 12×12 cm FOV, and a 128×128 matrix.

*In vivo* biocompatibility of the nanobeacon
--------------------------------------------

To evaluate the *in vivo* biocompatibility of the nanobeacon, at 72 h after intravenous injection of the IPP/MB nanobeacon (30 μg Fe mL^-1^, in 100 μL saline) or saline (100 μL), blood samples were collected from all groups of mice for a complete blood count analysis (red blood cells, white blood cells, platelets, mean platelet volume, hematocrit, hemoglobin, mean corpuscular volume, the percentage of intermediate cells, and mean corpuscular hemoglobin concentration). Afterward, all the mice were sacrificed, and the main organs (heart, liver, spleen, lungs, and kidneys) and tumors were collected in 10% neutral formalin. For H&E staining, paraffin-embedded tumor sections were stained and then observed and captured under a bright-field microscope with a digital camera (BA200 Digital, MOTIC, China).

Statistical analysis
--------------------

Each experiment was performed at least three times. All of the data were expressed as the means ± SEM using GraphPad Prism software, version 6.0. Statistical analyses were performed using the *t*-test or one-way analysis of variance with post hoc multiple comparisons. Significant differences between groups were considered at a minimum value of P\<0.05.

Results and discussion
======================

Design and characterization of the HSP90α molecular beacon
----------------------------------------------------------

The potential secondary structures and the target sequence recognition ability of the HSP90α mRNA- specific molecular beacon (HSP90-MB) were predicted using NUPAK [@B36]. NUPAK indicated that, without target sequence, the HSP90-MB was likely to form a "stem and loop" conformation under physiological conditions (\[Na^+^\] = 154mM), and unfold to a more stable conformation after molecular beacon- target sequence hybridization (Figure [2](#F2){ref-type="fig"}A-B and Figure [S1](#SM0){ref-type="supplementary-material"}A-E).

A 5\'- fluorophore (Alexa Fluor 488) and a 3\'- quencher (BHQ1) were modified to the 34 bases oligonucleotide (Table [S1](#SM0){ref-type="supplementary-material"}), and the distance between Alexa Fluor 488 and BHQ1 was close enough to cause Förster resonance energy transfer (FRET) when the HSP90-MB was at "stem and loop" conformation. In this case, fluorescence of Alexa Fluor 488 was quenched by BHQ1, and the molecular beacon was at "OFF" state (fluorescence quenched) (Figure [2](#F2){ref-type="fig"}A). While with target sequence, the "loop" part of HSP90-MB could recognize and hybridize with target sequence through base-pairing interaction, and the "stem" part of HSP90-MB could be separated. In this case, the distance between Alexa Fluor 488 and BHQ1 was increased, and the fluorescence of Alexa Fluor 488 was recovered, the molecular beacon was at "ON" state (fluorescence recovered) (Figure [2](#F2){ref-type="fig"}B).

In addition, the free energy of secondary structure of those two conformations was calculated with NUPAK, and the result showed a -23.38 kcal/mol energy difference between "ON" and "OFF" states of HSP90-MB.

To verify the ability of HSP90-MB to quantitatively recognize target sequence, an MB-target hybridization experiment with increasing concentrations of the oligonucleotide targets was performed. The fluorescence intensity of HSP90-MB increased in a target concentration-dependent manner after MB-target hybridization (Figure [2](#F2){ref-type="fig"}C). To examine the specificity of HSP90-MB, increasing concentrations of target, mismatched or non-target sequences were incubated with HSP90-MB. The recovery of HSP90-MB fluorescence intensity was more significant in MB-target hybridization than in mismatched or non-target groups (Figure [2](#F2){ref-type="fig"}D). These results indicated that, the fluorescence intensity of HSP90-MB was specific to target sequence and in a target concentration-dependent manner.

Synthesis and characterization of the IPP/MB nanobeacon
-------------------------------------------------------

Synthesis of the IPP/MB nanobeacon was mainly divided into the following steps: preparation of the iron oleate precursor, synthesis and purification of iron oxide nanocubes [@B37], aqueous phase transfer [@B38], PAMAM conjugation [@B39], surface modification with Pluronic P123 [@B40], and electrostatic interaction between nanocubes and HSP90-MB. Briefly, the oleate acid coated iron oxide nanocube (IONC-OA) was synthesized by thermal decomposition of iron oleate precursor with surfactants (oleic acid and sodium oleate) in a high-boiling solvent (1-octadecene, B.P. = 315 °C). The thermal decomposition process was controlled by a home-made PID controller based on Arduino (Figure [S2](#SM0){ref-type="supplementary-material"}). IONC-OA was well dispersed in n-hexane without aggregation. TEM images showed the uniform cube shape of IONC-OA with an edge length of 10.7±1.0 nm (Figure [3](#F3){ref-type="fig"}A).

After ligand-exchange with DMSA, thiol and carboxyl groups were anchored to the surface of the nanocubes (IONC-DMSA, denoted as ID), which provided aqueous dispersibility and sites for further conjugation. In addition, IONC-DMSA dispersed less stably in acid solution (pH \< 3.0) (Figure [S4](#SM0){ref-type="supplementary-material"}), which may be due to neutralization of the carboxylate groups under acidic conditions, thus weakening the repulsion of negative charges from surface carboxyl groups [@B41]. PAMAM was conjugated to IONC-DMSA via EDC/sulfo-NHS chemistry. The activation of carboxyl groups was performed in DMSO to avoid particle aggregation, after which IONC-DMSA was added dropwise to PAMAM in PBS (pH 7.4). The successful crosslinking between PAMAM and IONC-DMSA (IONC-PAMAM, denoted as IP) was indicated by a Zeta potential reversal from -40 mV to +40 mV (Figure [4](#F4){ref-type="fig"}A) and amide bond formation was confirmed by FT-IR (Figure [4](#F4){ref-type="fig"}B). Interestingly, IONC-PAMAM disperses better in acidic solutions than in alkaline solutions (*e.g.,* pH 10.0) due to the high density of surface amino groups on PAMAM (Figure [S4](#SM0){ref-type="supplementary-material"}). The high surface charge limited the application of IONC-PAMAM and could be improved via Pluronic P123 decoration [@B42]. The successful fabrication of IONC-PAMAM-P123 (denoted as IPP) was indicated by a decrease in Zeta potential to +20 mV (Figure [4](#F4){ref-type="fig"}A) and confirmed by FT-IR (Figure [4](#F4){ref-type="fig"}B). Furthermore, IPP was fairly stable over wide ranges of pH 3.0-10.0 (Figure [S4](#SM0){ref-type="supplementary-material"}). In addition, thermogravimetric analysis (TGA) was performed to estimate the number of modification molecules on the surface of nanocubes; the DTG peaks of ID, IP and IPP increased in a synthetic procedure manner (Figure [4](#F4){ref-type="fig"}C). The XRD patterns of ID, IP and IPP were measured and confirmed the IONC core had the same crystalline structure as synthetic magnetite (Fe^2+^Fe^3+^~2~O~4~, PDF\#19-0629) (Figure [S3](#SM0){ref-type="supplementary-material"}).

The IPP/MB nanobeacon was constructed by electrostatic interaction between the positively charged of PAMAM inside IPP and the negatively charged HSP90-MB at the appropriate mass ratio. The optimal mass ratio of iron in IPP to HSP90-MB was determined to be 16:1 by agarose gel electrophoresis (Figure [4](#F4){ref-type="fig"}D), in which HSP90-MB was completely condensed into the IPP. Under this mass ratio, approximately 16\~17 HSP90-MBs was condensed into each IPP. The calculation of the HSP90-MB content in IPP/MB nanobeacons was in [Supporting Information](#SM0){ref-type="supplementary-material"}.

As cationic polymer, PAMAM can from complexes with oligonucleotides [@B43], and Pluronic P123 decoration can inhibit nonspecific protein adsorption by forming a non-ionic hydrophilic shell [@B40], thus may protect HSP90-MB from degradation under physiological conditions. To examine the oligonucleotides protection ability of IPP nanoparticles, another agarose gel electrophoresis assay was performed according to our previous study [@B16], and the result showed IPP nanoparticles could protect HSP90-MB from DNase I degradation at the mass ratio of 16:1 (Figure [S5](#SM0){ref-type="supplementary-material"}).

To examine the magnetic property of the nanobeacon, field and temperature dependent magnetization curves of IONC-OA were recorded. The hysteresis curves showed superparamagnetism of the nanocubes in the range from -7 T to 7 T (Figure [5](#F5){ref-type="fig"}A), while the zero-field-cooled (ZFC) and field-cooled (FC) curves confirmed the superparamagnetic property appears at above 200 K (Figure [5](#F5){ref-type="fig"}B).

According to a study of Kim, et al. [@B44], the size of iron oxide nanoparticles have significant influences on both longitudinal relaxivity (r~1~) and transverse relaxivity (r~2~). In a range of 2.2 to 12 nm, the r~1~ relaxivity was decreased while the r~2~ relaxivity was increased as the size of iron oxide nanoparticles increases. To further investigate the capability of nanobeacon as an MRI contrast agent, *T*~1~ and *T*~2~ relaxation time measurement of ID, IP, and IPP were performed by a clinical 3T MR imaging device (Figure [S6](#SM0){ref-type="supplementary-material"}A and Figure [5](#F5){ref-type="fig"}C), and the r~1~ relaxivity and r~2~ relaxivity were determined by the linear fitting of 1/*T*~1~ and 1/*T*~2~ as a function of the Fe concentration (Figure [S6](#SM0){ref-type="supplementary-material"}B and Figure [5](#F5){ref-type="fig"}D).

Interestingly, r~2~ increased and r~1~ decreased after PAMAM conjugation and surface modification with Pluronic P123. As a result, IPP showed not only the highest r~2~ value of 109.1 mM^-1^s^-1^ (Figure [5](#F5){ref-type="fig"}D), but also the highest r~2~/r~1~ ratio of 53.19 (Figure [5](#F5){ref-type="fig"}E). Those results indicated the potential of IPP as a *T*~2~-weighted MRI contrast agent. It could be that after PAMAM conjugation and Pluronic P123 modification, the iron oxide core becomes more efficient at dephasing the spins of surrounding water protons, thus enhancing *T*~2~ relaxation times [@B45].

*In vitro* cytotoxicity and hemolytic analysis of the IPP/MB nanobeacon
-----------------------------------------------------------------------

The cytotoxicity of IONC-DMSA, PAMAM, IPP, and the IPP/MB nanobeacon were examined with a cell proliferation assay performed on cancer (MDA- MB-231) and normal (MCF-10A) cell lines (Figure [6](#F6){ref-type="fig"}A-B) [@B46]. The results indicated the IPP/MB nanobeacon had good cytocompatibility (cell viability \> 80%) at concentrations up to 100 μg Fe mL^-1^ in both cell lines. Next, the hemocompatibility of IONC-DMSA, IPP, and the IPP/MB nanobeacon were evaluated with the hemolysis assay (Figure [6](#F6){ref-type="fig"}C-D). The IPP/MB nanobeacon clearly did not show appreciable hemolytic activity at concentrations up to 10 μg Fe mL^-1^, with a corresponding hemolytic percentage of 4.63%. These results reveal that the IPP/MB nanobeacon showed negligible hemolytic activity and cytotoxicity in a concentration range of 0.5-10 μg Fe mL^-1^. Therefore, it was deemed suitable for further biomedical applications.

Real-time quantitative detection and imaging of HSP90α mRNA*in vitro*
---------------------------------------------------------------------

The IPP/MB nanobeacon was incubated with the MDA-MB-231 or MCF-10A cell line to verify cellular uptake behavior. The results showed that MDA-MB- 231 cells uptake 1.8-fold more nanobeacon than MCF-10A cells (Figure [S7](#SM0){ref-type="supplementary-material"}), which was consistent with previous studies [@B22], [@B47].

Since certain HSPs (such as HSP90) are overexpressed by malignant cells rather than normal cells, *q*RT-PCR analysis for HSP90AA mRNA level in the two cell lines was performed, which confirmed that the HSP90AA expression level in MDA-MB-231 cells was 4.7-fold higher than that in MCF-10A cells (Figure [7](#F7){ref-type="fig"}A).

Based on those findings, IPP nanoparticle was used as non-viral oligonucleotide delivery vector to transfer HSP90-MB into MDA-MB-231 or MCF-10A cells, to examine the HSP90α mRNA quantitative detection property of HSP90-MB in living cells.

Confocal microscopy was used to detect and visualize IPP/MB nanobeacon uptake and HSP90AA mRNA expression in the two cell lines. After a 48-h incubation, the fluorescence of Alexa Fluor 488 (labeled at the 5\' end of HSP90-MB) was observed via confocal microscopy in MDA-MB-231 cells, while MCF-10A cells remained dark, which indicated that the IPP/MB nanobeacon was sensitive and specific enough to distinguish the HSP90α mRNA levels between MDA-MB-231 and MCF-10A *in vitro* (Figure [7](#F7){ref-type="fig"}B).

Further examination of the subcellular localization of the IPP/MB nanobeacon showed the nanobeacon was first located endosomes and lysosomes at 24 h and escaped to the cytoplasm after a 48-h incubation (Figure [7](#F7){ref-type="fig"}E and Figure [S8](#SM0){ref-type="supplementary-material"}). The endosomal/lysosomal escape of the IPP/MB nanobeacon could be explained by the proton sponge mechanism of the PAMAM dendrimer [@B48]. Quantitative analysis for fluorescence of the IPP/MB nanobeacon in the two cell lines was performed by flow cytometry, which showed that green fluorescent (IPP/MB-positive) cells were 9.6-fold more abundant in the MDA-MB-231 line (Figure [7](#F7){ref-type="fig"}C-D). In consideration of the different cellular uptake profiles of these two cell lines, there was still 5.3-fold more positive cells in the MDA-MB-231 line than in MCF-10A, consistent with the *q*RT-PCR results. Taken together, these results suggested that the IPP/MB nanobeacon was capable of quantitative detection and imaging of mRNA expression levels in living cells. The fluorescence of nanobeacon is "ON" at cells that overexpression of HSP90α and "OFF" at HSP90α low-expression cells. Therefore, it is suitable for visualization of the difference between cancer and normal cells *in vitro*.

Regulating intracellular mRNA and protein levels of HSP90α *in vitro*
---------------------------------------------------------------------

Next, the ability of IPP/MB nanobeacon to regulate mRNA and protein levels of HSP90α was further investigated. MDA-MB-231 cells were incubated with the IPP/MB nanobeacon (10 μg Fe mL^-1^, 54 nM of HSP90-MB) for 48 h. Then, total mRNA was collected and *q*RT-PCR analysis for HSP90α mRNA was performed as mentioned above. The results showed that HSP90α mRNA levels were depleted by 76.9% compared to non-treated cells (Figure [8](#F8){ref-type="fig"}A). This consisted with previous studies showing, in the case of molecular antisense that mRNA binding leads to enzyme activity, which degrades DNA/RNA hybrids [@B49]. Western blotting and immunofluorescence staining confirmed that protein levels of HSP90α decreased significantly after incubation with the IPP/MB nanobeacon (Figure [8](#F8){ref-type="fig"}B-D), which could be explained as either translation inhibition or mRNA depletion [@B50]. Since the IPP/MB nanobeacon can efficiently downregulate HSP90α mRNA and protein levels, it might be applied to enhance the sensitivity of chemotherapy and hyperthermia, a benefit for cancer treatment in the future.

In vivo *T~2~*-weighted MR imaging in a tumor model
---------------------------------------------------

The potential of the IPP/MB nanobeacon to act as a *T*~2~-weighted MR imaging contrast agent was explored on a xenografted MDA-MB-231 tumor model. *T*~2~- weighted MR images of the tumor-bearing mice were obtained before and at different time points after injection of either IPP/MB or saline (Figure [9](#F9){ref-type="fig"}A). These images showed a decline of MR signal intensity (became darker on images) at the tumor site within the first 6 h after IPP/MB injection, after which the signal intensity slowly recovered up to 24 h post-injection. Quantitative analysis of the *T*~2~- weighted MR images revealed the IPP/MB injection gradually decreased the signal intensity from 92.8% (2 h) to 75.6% (6 h), and eventually increased to 88.1% (24 h) (Figure [9](#F9){ref-type="fig"}B). These results suggested that the IPP/MB nanobeacon could accumulate at the tumor site via the EPR effect *in vivo*, thus allowing for *T*~2~-weighted MR imaging of tumors [@B51].

*In vivo* biocompatibility of IPP/MB nanobeacon
-----------------------------------------------

The biocompatibility of the IPP/MB nanobeacon was also evaluated *in vivo*. A complete blood count analysis, which included red blood cells (RBC), white blood cells (WBC), lymphocytes (Lymph), platelets (PLT), mean platelet volume (MPV), hematocrit (HCT), hemoglobin (HGB), mean corpuscular volume (MCV), as well as the mean corpuscular hemoglobin concentration (MCHC), showed no significant difference in the levels of these indicators between saline and IPP/MB treatment (Figure [S9](#SM0){ref-type="supplementary-material"}). Moreover, major organs (heart, liver, spleen, lungs, and kidneys) and tumors from mice treated with saline or the IPP/MB nanobeacon were collected, and H&E staining was performed (Figure [9](#F9){ref-type="fig"}C). Neither pathological tissue damage nor inflammation was observed in either group, suggesting that the IPP/MB nanobeacon had no acute systemic toxicity for mice at a dose of 3 mg Fe kg^-1^.

Conclusions
===========

In this study, we designed and synthesized a new kind of superparamagnetic nanobeacon for HSP90α mRNA detection and regulation in living cells, as well as enhancement of *T*~2~-weighted MR Imaging in a tumor model. The IPP/MB nanobeacon showed negligible hemolytic activity and cytotoxicity *in vitro* and had no acute systemic toxicity *in vivo*, exhibiting good biocompatibility and hemocompatibility. Confocal microscopy and flow cytometry analysis confirmed that the IPP/MB nanobeacon was able to distinguish HSP90α mRNA levels in living cells and was thus suitable for visualizing the difference between cancer and normal cells. Importantly, the IPP/MB nanobeacon was also capable of efficiently down-regulating HSP90α mRNA and protein levels, which might be beneficial for the sensitization of chemotherapy and hyperthermia of cancer. In addition, *T*~2~-weighted MR imaging ability was increased after PAMAM conjugation and Pluronic P123 modification, which allowed the IPP/MB nanobeacon to enhance *T*~2~-weighted MR image contrasts of tumors *in vivo*. Altogether, the IPP/MB nanobeacon showed promise for future applicability for tumor-related mRNA detection, regulation and multiscale imaging in the field of cancer diagnostics and therapeutics.
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:   magnetic resonance imaging
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PDI

:   polydispersity index

PEI

:   polyethylenimine

PLGA

:   poly(lactic-co-glycolic acid)

PLT
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PVDF

:   polyvinylidene fluoride or polyvinylidene difluoride

qRT-PCR

:   quantitative real-time polymerase chain reaction
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:   red blood cells

SDS-PAGE

:   sodium dodecyl sulfate polyacrylamide gel electrophoresis

SE-IR

:   spin echo-inversion recovery

SEM

:   standard error of the mean

SPF

:   specific-pathogen-free

SQUID

:   superconducting quantum interference device

sulfo-NHS

:   N-hydroxysulfosuccinimide sodium salt

TBST

:   a mixture of tris-buffered saline and Tween 20

TEM

:   transmission electron microscope

TGA

:   thermogravimetric analysis

TMB

:   3,3\',5,5\'-tetramethylbenzidine

TNBC

:   triple negative breast cancer

TRAIL

:   TNF-related apoptosis-inducing ligand
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:   white blood cells

XRD
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![Schematic of the IONC-PAMAM-P123/HSP90α molecular beacon (IPP/MB nanobeacon) fabrication; the detection, imaging and downregulation of HSP90α mRNA in living cells, and enhanced *T*~2~-weighted MR imaging in a tumor model.](thnov09p5784g001){#F1}

![**Design and characterization of the HSP90α mRNA-specific molecular beacon. (A, B)** Potential secondary structures and target sequence recognition of the HSP90α mRNA-specific molecular beacon. **(C)** Target concentration-dependent fluorescence recovery of the HSP90AA molecular beacon was examined by beacon-target hybridization experiments, **(D)** the specificity of the molecular beacon was examined by beacon-target/single-base mismatch/nontarget hybridization experiments. The data are presented as the mean ± SEM.](thnov09p5784g002){#F2}

![**TEM images of the fabrication of nanobeacons. (A)** IONC-OA, **(B)** IONC-DMSA (ID), **(C)** IONC-PAMAM (IP), and **(D)** IONC-PAMAM-P123 (IPP). Scale bar = 50 nm.](thnov09p5784g003){#F3}

![**Characterization of the ID, IP, IPP and IPP/MB nanobeacon. (A)** DLS analysis of the size and Zeta potential of ID, IP, IPP and IPP/MBs. The data are presented as the mean ± SEM. **(B)** IR spectra of ID, IP and IPP. **(C)** TG and DTG analysis of ID, IP, and IPP nanoparticles. Solid curves for mass losses; dashed curves for DTGs. **(D)** Condensation ability and mass ratio of IPP to MB was determined by agarose gel electrophoresis, and the quantitative assay was performed by measuring the intensity of agarose gel electrophoresis images using ImageJ software. The data are presented as the mean ± SEM.](thnov09p5784g004){#F4}

![**Magnetic property of IONC-OA and *T*~2~-weighted MR imaging of ID, IP and IPP. (A, B)** Magnetic hysteresis and FC/ZFC assay confirmed the superparamagnetic property of the IONC core above 200K. **(C, D)** *T*~2~-weighted MR imaging and transverse relaxivity (r~2~) of ID, IP and IPP was examined by a clinical 3T MR imaging device with a *T*~2~ mapping sequence. The data are presented as the mean ± SEM. **(E)** r~2~/r~1~ ratio of ID, IP and IPP. The data are presented as the mean ± SEM.](thnov09p5784g005){#F5}

![**Cytotoxicity and hemolytic analysis of the nanobeacon. (A, B)** Cell proliferation assay showed that cell viability was not compromised in neither cancerous nor normal cell lines after incubations with IONC-DMSA, PAMAM, IPP, and the IPP/MB nanobeacon for 48 h. The data are presented as the mean ± SEM. **(C, D)** Hemolytic assay indicated the nanobeacons have good hemocompatibility. The data are presented as the mean ± SEM.](thnov09p5784g006){#F6}

![**Real-time quantitative detection and imaging of HSP90 mRNA *in vitro*. (A)** Different expression levels of HSP90AA in MDA-MB-231 and MCF-10A cell lines was confirmed by *q*RT-PCR. The data are presented as the mean ± SEM. \*\**P*\<0.01. **(B)** CLSM images showed that high expression of HSP90 mRNA in MDA-MB-231 cells was detected by the nanobeacons while MCF-10A cells remained dark. Scale bar = 10 μm. **(C, D)** The fluorescence properties of the MDA-MB-231 and MCF-10A cell lines after incubating with nanobeacons were further examined by flow cytometry. The data are presented as the mean ± SEM. \*\**P*\<0.01. **(E)** LSCM and 3D reconstructed images of MDA-MB-231 cells incubated with the nanobeacon for 4 h, 24 h and 48 h showed the intracellular location and distribution of the nanobeacon. Scale bar = 10 μm.](thnov09p5784g007){#F7}

![**Down-regulation of HSP90 mRNA and protein levels *in vitro*. (A)** *q*RT-PCR confirmed the expression level of HSP90AA mRNA was down-regulated by IPP/MB treatment. The data are presented as the mean ± SEM. \*\**P*\<0.01. **(B-D)** Western blotting and immunofluorescence staining assay confirmed that the protein levels of HSP90α decreased significantly after incubation with the IPP/MB nanobeacon. Scale bar = 20 μm. The data are presented as the mean ± SEM. \*\**P*\<0.01.](thnov09p5784g008){#F8}

![***In vivo T*~2~-weighted MR imaging and biocompatibility of the IPP/MB nanobeacon. (A)** Images of the *T*~2~-weighted MR imaging of a tumor model before and at different time points after injection of either IPP/MB or saline. **(B)** Quantitative analysis of the MRI signal intensity of the tumor sites at different time points after IPP/MB administration, relative to the corresponding time points after saline administration. The data are presented as the mean ± SEM. **(C)** H&E staining of major organs (heart, liver, spleen, lung and kidney) and tumors from mice treated with saline or the IPP/MB nanobeacon. Scale bar = 100 μm.](thnov09p5784g009){#F9}
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